Middle East crisis threatens Indian pharma with temporary API (Active Pharmaceutical Ingredient),cost spikes while chemicals face export disruptions, as $1.75B MENA exports (6% of FY25's $30.47B total), shipping delays via Hormuz/Suez, and energy/logistics inflation hit supply chains, with API manufacturers facing 25% power cost exposure.

Pharma: API & Contract Manufacturing Under Pressure

Supply chain vulnerabilities exposed

• Europe KSMs/APIs routed via Middle East/Suez face 10–15 day delays; biologics/vaccines hit hardest by temperature control risks.
• Petrochemical solvents/intermediates prices up due to crude spike; API makers see 25% cost inflation from power alone.
• MENA exports ($1.75B): UAE, Saudi, Iraq markets see port delays + payment risks; generics critical to regional health systems.

Industry response: 3–6 month inventory buffers (COVID lesson) provide short-term cushion, but prolonged conflict risks production halts. ​

Chemicals: Easy Pass-Through But Export Volatility

Commodity chemicals

• Petrochemical derivatives (solvents, packaging): Direct crude linkage allows margin-neutral pass-through to customers.
• Freight 3–5x surge: Air cargo for time-sensitive chemicals becomes prohibitively expensive.

Specialty chemicals

• MENA exports disrupted: Gulf refineries (key buyers) face operational issues; Iran payments frozen.
• Earnings volatility: Short-term revenue dip but long-term pricing power intact due to niche positioning.

Analyst view: Chemicals more resilient than pharma due to pricing flexibility, but working capital stress from delayed receivables. ​

Strengths of Indian Pharma/Chemicals

• 3–6 month inventory buffers provide short-term supply security.

• Chemical pass-through pricing neutralizes crude cost spikes.
• US/Europe demand intact; MENA represents only 6% pharma exports.
• PLI scheme progress: Penicillin-G, APIs reducing China dependence.
• Temperature-controlled logistics experience from COVID era.

Risks from Prolonged Middle East Crisis

• API production halt if European KSMs delayed beyond inventory buffers.

• 25% power cost spike cripples API manufacturer margins.
• Rupee depreciation worsens imported input inflation.
• MENA payment defaults freeze working capital for exporters.
• Biologics/vaccine spoilage risk from extended shipping times.

Impact Scenarios & Company Exposure

Short-term (1–3 months)

• Pharma: 2–5% cost inflation (manageable with buffers)
• Chemicals: Neutral (pass-through offsets crude)
• MENA exports: 10–20% volume dip

Medium-term (3–6 months)

• Pharma: API shortages → 5–10% price hikes
• Chemicals: Gulf market share loss to China/S Korea
• Earnings: 3–7% EPS compression (selective)

High exposure: API makers (Aarti Drugs, Granules), MENA-focused exporters (Neuland Labs, Suven Life Sciences).